Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Agomelatine is efficacious in reducing symptoms and preventing relapse in placebo-controlled trials in generalised anxiety disorder (GAD). Nevertheless, fixed dose studies of agomelatine in GAD have not been undertaken. To determine the minimally effective optimal dose of agomelatine in GAD, the efficacy of two doses of agomelatine (10 and 25mg/day) was investigated in a 12-week, placebo-controlled, double-blind, international study in patients with a primary diagnosis of GAD. The primary outcome measure was the Hamilton Anxiety scale (HAM-A). The study was undertaken in 35 clinical centers in Finland, Russia, Poland, Slovakia and Ukraine from August 2013 to January 2015. 131 out-patients were included in the agomelatine 10mg group, 139 in the agomelatine 25mg group, and 142 in the placebo group. Both doses of agomelatine were associated with significant decreases in the HAM-A at week 12 (difference versus placebo of 7.16±1.00 at 10mg and 11.08±0.98 at 25mg, p<0.0001). Significant effects on all secondary measures were found for both doses at week 12; including psychic and somatic HAM-A subscales, response rate, remission on the HAM-A, and functional impairment. Findings were confirmed in subsets of more severely ill patients on all endpoints. The low placebo response rate observed in this study was consistent with an increase in the quality of data collected. Agomelatine was well-tolerated by patients, with minimal distinctions from placebo. There was a dose effect of agomelatine, with a greater placebo-agomelatine difference in the agomelatine 25mg group, compared to the agomelatine 10mg group.The present data support early work indicating the efficacy and tolerability of agomelatine in the treatment of GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 1×
“GAD is the most common anxiety disorder in primary care practice (Hoffman et al., 2008; Wittchen et al., 2011), and is often associated with both comorbidity (including comorbidity of major depression and other anxiety disorders) and morbidity (including psychosocial impairment and economic costs)…”
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Human and economic burden of generalized anxiety disorder
Hoffman, D. L., Dukes, E. M., & Wittchen, H.-U. (2008) · Depression and Anxiety · doi:10.1002/da.20257 · Cited by 438
Dechartres, A., Boutron, I., Trinquart, L., Charles, P., & Ravaud, P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-1-201107050-00006 · Cited by 307 · cited 1×
“A broader spectrum of geographical locations and clinical settings, and a higher number of centers may help increase generalizability of the findings (ICH E9, 1999) but it may also add to variance in the data (Dechartres et al., 2011).”
Fava, M., Rush, A. J., Alpert, J. E., Carmin, C. N., Balasubramani, G., Wisniewski, S. R., Trivedi, M. H., Biggs, M. M., & Shores-Wilson, K. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605101304 · Cited by 183 · cited 1×
“Anxiety symptoms are common in major depression (Fava et al., 2006; Stein and Hollander, 2002) and a range of work has demonstrated that in patients with MDD agomelatine is significantly more efficacious than both placebo and several comparator antidepressants in reducing anxiety symptoms (Hale et…”
Stein, D. J., Ahokas, A., Albarran, C., Olivier, V., & Allgulander, C. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07493 · Cited by 94
Self-citationAgomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Stein, D. J., Ahokas, A., Márquez, M. S., Höschl, C., Oh, K. S., Jarema, M., Avedisova, A. S., Albarran, C., & Olivier, V. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08433 · Cited by 67
Hoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Cited by
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
Carl, E., Witcraft, S. M., Kauffman, B. Y., Gillespie, E. M., Becker, E. S., Cuijpers, P., Van Ameringen, M., Smits, J. A. J., & Powers, M. B. (2020) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2018.1560358 · Cited by 151
Agomelatine for the treatment of generalized anxiety disorder
Buoli, M., Grassi, S., Serati, M., & Altamura, A. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359257 · Cited by 61
Metadata
- Authors
- Stein, D. J., Ahokas, A., Jarema, M., Avedisova, A. S., Vavrusova, L., Chaban, O., Gruget, C., Olivier, V., Picarel-Blanchot, F., & de Bodinat, C.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 27
- Issue
- 5
- Pages
- 526-537
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2592525547
- Cited by
- 39
- References
- 8
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1016/j.euroneuro.2017.02.007
- The paper
- Stein, D. J., Ahokas, A., Jarema, M., Avedisova, A. S., Vavrusova, L., Chaban, O., Gruget, C., Olivier, V., Picarel-Blanchot, F., & de Bodinat, C. (2017). Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2017.02.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.